L

Liquidia Corporation Tech Stack

Public biotech commercializing inhaled therapies for pulmonary hypertension

Biotechnology Research Morrisville, NC 51–200 employees Founded 2004 Public Company

Liquidia is a public biopharmaceutical company with an FDA-approved inhaled treprostinil powder (YUTREPIA) for pulmonary arterial hypertension and related lung disease, now scaling sales and regulatory infrastructure. The hiring mix—dominated by sales (22 roles) with secondary focus on healthcare, legal, and manufacturing—reflects a commercial-stage company ramping field teams and navigating complex drug-device combination product compliance across global markets.

Tech Stack 10 technologies

Core StackVeeva Microsoft Office Steam Excel PowerPoint HPLC Veeva PromoMats Veeva CRM

What Liquidia Corporation Is Building

◆Challenges

Ensuring regulatory compliance for drug-device combos
Growing sales in territory
Commercializing novel therapies
Regulatory compliance across global markets
Compliance with fda regulations
Reducing downtime
Managing regulatory submissions
Increasing sales in pulmonary hypertension
Maintaining gmp compliance
Risk mitigation

▲Active Projects

Yutrepia program
Regulatory submission strategy development
Risk assessments and mitigation strategies for global cmc and device regulatory matters
Global regulatory strategy for drug-device combos
Preparation of module 2/3 documentation
Specialty pharmacy education and support
Sales data collection & publication
Sales force sizing exercises
Developing field sales tools with veeva solutions
Annual medical plan development

Hiring Activity

Accelerating55 roles · 25 in 30d

Department

Sales

22

Healthcare

7

Legal

5

Manufacturing

4

Ops

4

Finance

2

Logistics

2

Marketing

2

Seniority

Mid

25

Senior

14

Director

9

Manager

3

Junior

1

Notable leadership hires: Regulatory Affairs Director

Company intelligence

Find more companies like Liquidia Corporation by tech stack, pain points and active projects

Get started free

About Liquidia Corporation

Liquidia develops and commercializes inhalation therapies for rare cardiopulmonary diseases, anchored by YUTREPIA (treprostinil inhalation powder) for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also operates Liquidia PAH, a subsidiary handling commercialization of generic treprostinil formulations. A second-generation candidate, L606, is in development as a twice-daily liposomal treprostinil with a next-generation nebulizer for North American markets. Core operations span drug formulation, device integration, regulatory affairs, specialty pharmacy support, and direct sales across U.S. markets.

HeadquartersMorrisville, NC

Company Size51–200 employees

Founded2004

Hiring MarketsUnited States

Frequently Asked Questions

What is Liquidia's main product?

YUTREPIA (treprostinil inhalation powder), FDA-approved for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company also commercializes generic treprostinil injection via subsidiary Liquidia PAH.

What tech does Liquidia use?

Veeva (CRM and PromoMats), Microsoft Office suite (Excel, PowerPoint), HPLC for analytical work, and Steam. The stack reflects clinical trial management and field sales infrastructure typical of commercial-stage biotech.